Localized Infant Neuroblastomas Often Show Spontaneous Regression: Results of the Prospective Trials NB95-S and NB97

Hero, Barbara; Simon, Thorsten; Spitz, Ruediger; Ernestus, Karen; Gnekow, Astrid; Scheel-Walter, Hans-Guenther; Schwabe, Dirk; Schilling, Freimut H.; Benz-Bohm, G.; Berthold, Frank

doi:10.1200/jco.2007.12.3349

Cited by 279 publications

(197 citation statements)

References 36 publications

Supporting

Mentioning

178

Contrasting

Unclassified

Order By: Relevance

“…In LNESG1 only one of three deaths in patients with INSS stage 1 disease was due to tumour progression, the other two were related to treatment [6]. Today we believe that a substantial number of our patients would have survived if they had been followed with observation only [13,14]. Accordingly it is still a major challenge to maintain the current high survival rates with reduced treatment [15].…”

Section: Discussionmentioning

confidence: 99%

Influence of image‐defined risk factors on the outcome of patients with localised neuroblastoma. A report from the LNESG1 study of the European International Society of Paediatric Oncology Neuroblastoma Group

Monclair

Mosseri

Cecchetto

et al. 2015

Pediatric Blood & Cancer

View full text Add to dashboard Cite

BackgroundThe European multicenter study LNESG1 was designed to evaluate the safety and efficacy of surgical treatment alone in patients with localised neuroblastoma. In a retrospective, observational study we examined the impact of image‐defined risk factors (IDRF) on operative complications and survival (EFS and OS).Procedure534 patients with localised, non‐MYCN amplified neuroblastoma were recruited between 1995 and 1999. Group 1 consisted of 291 patients without IDRF (Stage L1 in the International Neuroblastoma Risk Group (INRG) staging system), all treated with primary surgery. Group 2: 118 patients with IDRF (INRG Stage L2), also treated with primary surgery. Group 3: 125 patients in whom primary surgery was not attempted, 106 receiving neo‐adjuvant chemotherapy.ResultsIn L1 patients (Group 1) 5‐year EFS was 92% and OS 98%. In L2 patients (Group 2 and 3) EFS was 79% and OS 89%. The differences in both EFS and OS were significant. EFS and OS in Group 2 (86% and 95%) were significantly better than 73% and 83% in Group 3. In INSS stage 1, 2 and 3, EFS were respectively 94%, 81% and 76%. Except between stage 2 and 3 the differences were significant. OS were respectively 99%, 93% and 83%, all significantly different. The 17% operative complication rate in L2 patients was significantly higher than 5% in L1 patients.ConclusionsIn localised neuroblastoma, IDRF at diagnosis are associated with worse survival rates and higher rates of operative complications. The impact of IDRF should become an integrated part of therapy planning. Pediatr Blood Cancer 2015;62:1536–1542. © 2015 Wiley Periodicals, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

Influence of image‐defined risk factors on the outcome of patients with localised neuroblastoma. A report from the LNESG1 study of the European International Society of Paediatric Oncology Neuroblastoma Group

Monclair

Mosseri

Cecchetto

et al. 2015

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…In addition, a larger dataset, Kocak (cohort 5, n ¼ 649; ref. 38), was included to study the correlations between expression of CSF-1R and other markers.…”

Section: R2 Databasementioning

confidence: 99%

Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma

Mao

Eißler

Blanc

et al. 2016

Clinical Cancer Research

128

105

View full text Add to dashboard Cite

Purpose: Neuroblastoma is the most common extracranial solid cancer type in childhood, and high-risk patients have poor prognosis despite aggressive multimodal treatment. Neuroblastoma-driven inflammation contributes to the induction of suppressive myeloid cells that hamper efficient antitumor immune responses. Therefore, we sought to enhance antitumor immunity by removing immunosuppression mediated by myeloid cells.Experimental

show abstract

“…Клинически нейробластома -чрезвычайно гетерогенная опухоль -может спонтанно рег-рессировать или созревать без лечения [4,5], что позволяет занять выжидательную позицию (стратегия «see and wait») 1 [6,7]. Однако возмож-ны агрессивное течение и резистентность к совре-менной интенсивной мультимодальной терапии [8].…”

Section: обоснованиеunclassified

Treatment of High-Risk Neuroblastoma

Хижников¹,

Казанцев²

2017

Oncopediatria

View full text Add to dashboard Cite

show abstract

Localized Infant Neuroblastomas Often Show Spontaneous Regression: Results of the Prospective Trials NB95-S and NB97

Abstract: Spontaneous regression is regularly seen in infants with localized neuroblastoma and is not limited to the first year of life. A wait-and-see strategy is justified in those patients.

Cited by 279 publications

References 36 publications

Influence of image‐defined risk factors on the outcome of patients with localised neuroblastoma. A report from the LNESG1 study of the European International Society of Paediatric Oncology Neuroblastoma Group

Influence of image‐defined risk factors on the outcome of patients with localised neuroblastoma. A report from the LNESG1 study of the European International Society of Paediatric Oncology Neuroblastoma Group

Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma

Treatment of High-Risk Neuroblastoma

Contact Info

Product

Resources

About